Consistent with this, the expression levels of TRDV1 and TRDV3 were higher in B2MMUT compared with in B2MWT MMR-d cancers (two-sided Wilcoxon rank-sum test, P = 6.5 × 10−8 for all of the cohorts combined; two-sided linear regression, P = 4.7 × 10−6, adjusted for tumour type; Fig. 1d–f). This evidence concerns the gene TRDV3 and neoplasm.